Neurology
-
Randomized Controlled Trial Multicenter Study Comparative Study Clinical Trial
Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects.
Using identical methods, three simultaneous placebo-controlled trials of topiramate for painful diabetic neuropathy (PDN) did not reach significance. This independent yet concurrent placebo-controlled trial used different methods to assess topiramate efficacy and tolerability in PDN. ⋯ Topiramate monotherapy reduced pain and body weight more effectively than placebo in patients with painful diabetic neuropathy.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial.
To evaluate the efficacy and safety of the acetylcholinesterase inhibitor donepezil in a placebo-controlled trial in patients with mild cognitive impairment (MCI). ⋯ Although significant treatment effects were not seen in the primary efficacy measures, outcomes on secondary measures suggest promising directions for further evaluation of donepezil treatment in patients with MCI.
-
Multicenter Study Clinical Trial
A prospective analysis of the outcome of levetiracetam in clinical practice.
In this postlicensing surveillance study in a large unselected population, data were collected prospectively on all patients prescribed levetiracetam (LEV) at a regional epilepsy clinic over a 2-year period. Two hundred forty-five (69.2%) patients remained on LEV, with 8.8% achieving remission and some improvement in seizure control in 49.3%. ⋯ Cumulative probability of remaining on LEV at 12 months was 0.74 (95% CI 0.69 to 0.79). Factors predictive of a poorer retention were a greater number of previous antiepileptic drugs and a faster initial titration regimen.
-
Multicenter Study
Early neurologic deterioration in intracerebral hemorrhage: predictors and associated factors.
To identify potential predictors of and factors associated with early neurologic deterioration (END) in primary intracerebral hemorrhage (ICH). ⋯ Clinical and biologic markers of the inflammatory reaction on admission are predictors of subsequent END, whereas early ICH growth, intraventricular bleeding, and high systolic blood pressure within 48 hours are factors associated with END in patients with spontaneous ICH.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine.
Menstrually associated migraine (MAM) is often prolonged and difficult to manage with conventional therapies. Frovatriptan is a new selective 5HT(1B/1D) receptor agonist indicated for short-term management of migraine. It has a long half-life and good tolerability. These characteristics suggest that frovatriptan may be useful for the intermittent prevention of MAM. ⋯ Frovatriptan given prophylactically for 6 days was effective in reducing the incidence of menstrually associated migraine. More than half of patients who used frovatriptan 2.5 mg BID had no menstrually associated migraine headache during the 6-day perimenstrual period. The findings are consistent with the long duration of action and good tolerability of frovatriptan observed in short-term migraine management.